Dato-DXd

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerNon-Small Cell Lung CancerGastric CancerTriple-Negative Breast CancerUrothelial CarcinomaUrothelial Cancer

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Dato-DXd

AstraZeneca

Phase 3

42

Trodelvy

Gilead

Preclinical

373

Tykerb

GSK

Preclinical

804

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

785

Lexiscan

Astellas

Preclinical

16

Zolymbus

AbbVie

Preclinical

17

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—8

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

39

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

110

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting·AstraZeneca·Phase 3·NCT06417814·744 enrolled

A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI Therapy

Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT07535437·66 enrolled

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

Recruiting·AstraZeneca·Phase 2·NCT07098338·278 enrolled

Show 1 more trial

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting·AstraZeneca·Phase 2·NCT05061550·630 enrolled

Breast Cancer4 trials

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Active, not recruiting·AstraZeneca·Phase 3·NCT05104866·732 enrolled

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Recruiting·AstraZeneca·Phase 3·NCT07205822·100 enrolled

A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)

Active, not recruiting·AstraZeneca·Phase 3·NCT06112379·1,902 enrolled

Show 1 more trial

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Recruiting·AstraZeneca·Phase 3·NCT06103864·625 enrolled

Triple-Negative Breast Cancer3 trials

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Active, not recruiting·AstraZeneca·Phase 3·NCT05374512·644 enrolled

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Active, not recruiting·AstraZeneca·Phase 3·NCT05629585·1,174 enrolled

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT06508216·50 enrolled

Solid Tumors1 trial

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Recruiting·Daiichi Sankyo·Phase 1·NCT06244485·210 enrolled

Urothelial Cancer1 trial

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

Recruiting·Daiichi Sankyo·Preclinical·NCT07129993·630 enrolled

1 more indication

Gastric Cancer1 trial

DESTINY-Gastric02: T-DXd in Gastric Cancer

Completed·Daiichi Sankyo·Phase 2·NCT04644068·187 enrolled

Details

Drug Info

Related News